Modality
Peptide
MOA
BCL-2i
Target
IL-13
Pathway
Sphingolipid
HS
Development Pipeline
Preclinical
~Jul 2015
→ ~Oct 2016
Phase 1
~Jan 2017
→ ~Apr 2018
Phase 2
Jul 2018
→ Mar 2027
Phase 2Current
NCT05776913
989 pts·HS
2018-07→2027-03·Terminated
989 total pts1 indication
Phase 3
NDA/BLA
Approved
CompletedCurrentUpcoming
Catalysts (1)
2027-03-1011mo awayPh2 Data· HS
Trial Timeline
Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2
P2
Termina…
Catalysts
Ph2 Data
2027-03-10 · 11mo away
HS
Terminated|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT05776913 | Phase 2 | HS | Terminated | 989 | EFS |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-5501 | Pfizer | Phase 1 | BTK | |
| Lisonaritide | Eli Lilly | Phase 3 | IL-13 | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Geliderotide | Novartis | NDA/BLA | IL-17A | |
| Sovarapivir | AbbVie | Phase 2/3 | IL-13 | |
| Ceviderotide | Novo Nordisk | Preclinical | IL-13 | |
| Tezecilimab | Takeda | NDA/BLA | Tau | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| Rimaosocimab | Amgen | Preclinical | FXIa | |
| MRN-7601 | Moderna | Phase 2 | IL-13 |